Q4 EPS Estimates for Sensus Healthcare Cut by Roth Capital

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Stock analysts at Roth Capital cut their Q4 2025 earnings per share estimates for shares of Sensus Healthcare in a research report issued to clients and investors on Thursday, August 7th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.13 per share for the quarter, down from their prior estimate of $0.18. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. The business had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million.

A number of other research analysts have also issued reports on SRTS. Lake Street Capital reduced their price target on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd. Maxim Group reduced their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, HC Wainwright reduced their price target on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.

Sensus Healthcare Stock Down 1.5%

SRTS stock traded down $0.05 during trading on Monday, reaching $3.39. 23,915 shares of the company's stock were exchanged, compared to its average volume of 192,146. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.33. The company's fifty day moving average price is $4.72 and its 200-day moving average price is $4.91. The firm has a market cap of $55.73 million, a PE ratio of -57.00 and a beta of 1.34.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Sensus Healthcare during the second quarter worth $3,170,000. Acadian Asset Management LLC raised its position in shares of Sensus Healthcare by 35.3% during the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company's stock worth $2,225,000 after purchasing an additional 122,746 shares during the period. Renaissance Technologies LLC raised its position in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after purchasing an additional 21,600 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after purchasing an additional 88,953 shares during the period. Finally, Divisadero Street Capital Management LP raised its position in shares of Sensus Healthcare by 459.4% during the second quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company's stock worth $1,539,000 after purchasing an additional 266,635 shares during the period. Institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.